Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Storming the Castle with TCP

Frits van Rhee, Katie Stone

Blood (2019) 133 (16): 1697–1698.

https://doi.org/10.1182/blood-2019-02-900803

Published: 2019

Journal Articles

Characterization of the Immune Impact of Daratumumab By Mass Cytometry in Multiple Myeloma

Sarah K Johnson, PhD, Stephen Burke, PhD, Matthew Henry, M.S., Amy Greenway, Katie Stone, BS, Brian A Walker, PhD, Frits van Rhee, MD PhD, Gareth Morgan, MD

Blood (2018) 132 (Supplement 1): 4466.

https://doi.org/10.1182/blood-2018-99-119241

Published: 2018

Journal Articles

Myeloma Patient-Derived Bone Marrow Serum Negatively Regulates Natural Killer Cell Activity

Tarun K. Garg, PhD, Katie Stone, BS, Hongwei Wang, MS, Antje Hoering, PhD, Brian A Walker, PhD, Maurizio Zangari, MD, Sharmilan Thanendrarajan, MD, Carolina D. Schinke, MD, Faith E. Davies, MD, Gareth Morgan, MD, Frits van Rhee, MD PhD

Blood (2018) 132 (Supplement 1): 4468.

https://doi.org/10.1182/blood-2018-99-119692

Published: 2018

Journal Articles

Personalized Therapy in Multicentric Castleman Disease Produces Excellent Outcomes in a Tertiary Referral Center

Katie Stone, BS, Francisco Socola, MD, Amy Greenway, Samina Waheed, Kristen Carter, APRN, Diane Glendinning, APRN, Daisy Alapat, MD, Frits van Rhee, MD PhD

Blood (2018) 132 (Supplement 1): 3701.

https://doi.org/10.1182/blood-2018-99-119510

Published: 2018

Journal Articles

Treatment of Unresectable Unicentric Castleman Disease with Therapeutic Embolization

Meera Mohan, MD, James C Meek, MD, Mary Elizabeth Meek, MD, Ralph Lynn Broadwater, MD, Katie Stone, BS, Amy Greenway, Daisy Alapat, MD, Frits van Rhee, MD PhD

Blood (2018) 132 (Supplement 1): 2415.

https://doi.org/10.1182/blood-2018-99-119820

Published: 2018

Journal Articles

International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease

Blood (2018) 132 (20): 2115–2124.

https://doi.org/10.1182/blood-2018-07-862334

Published: 2018

Includes: Supplemental data

Journal Articles

The IL15 Superagonist Complex ALT-803 Potently Enhances the Proliferative Capacity and Activity of in Vitro Expanded Natural Killer Cells

Tarun K. Garg, PhD, Katie Stone, BS, Amy Greenway, Carolina D. Schinke, MD, Sharmilan Thanendrarajan, MD, Maurizio Zangari, MD, Joshua Epstein, DSc, Brian A Walker, PhD, Hing C Wong, PhD, Emily K Jeng, Niraj Shrestha, Faith E Davies, MD, Gareth J. Morgan, MD PhD, Frits van Rhee, MD PhD

Blood (2017) 130 (Supplement 1): 5452.

https://doi.org/10.1182/blood.V130.Suppl_1.5452.5452

Published: 2017

Journal Articles

Virome Capture Sequencing in Castleman Disease Identifies Associations with Herpesviridae Family Members but No Novel Viruses

Christopher Sheild Nabel, MD PhD, Stephen Sameroff, BS, Dustin Shilling, PhD, Jason R Ruth, PhD, Mitsuhiro Kawano, MD, Yasuharu Sato, MD, Noriko Iwaki, MD, Federico Valdivieso, BS, Michael Feldman, MD, Katie Stone, BS, Daisy Alapat, MD, Frits van Rhee, MD PhD, Amy Chadburn, MD, Signe Spetalen, MD, Alexander Fosså, MD PhD, W. Ian Lipkin, MD, David C Fajgenbaum, MDMBA,MSc

Blood (2017) 130 (Supplement 1): 3589.

https://doi.org/10.1182/blood.V130.Suppl_1.3589.3589

Published: 2017

Journal Articles

Quantification of Plasma Proteins from Idiopathic Multicentric Castleman Disease Flares and Remissions Reveals 'Chemokine Storm' and Separates Clinical Subtypes

Sheila K Pierson, MS, Aaron James Stonestrom, MDPhD, Jason R Ruth, PhD, Dustin Shilling, PhD, Hongzhe Li, PhD, Yue Ren, MS, Katie Stone, BS, Frits van Rhee, MD PhD, David C Fajgenbaum, MDMBA,MSc

Blood (2017) 130 (Supplement 1): 3592.

https://doi.org/10.1182/blood.V130.Suppl_1.3592.3592

Published: 2017

Journal Articles

Prolonged Remission Achieved in a Relapsing Idiopathic Multicentric Castleman Disease Patient with a Novel, Targeted Treatment Approach

David C Fajgenbaum, MDMBA,MSc, Dustin Shilling, PhD, Helen L Partridge, BS, Sheila K Pierson, MS, Jason R Ruth, PhD, Christopher Sheild Nabel, MD PhD, Katie Stone, BS, Vandana Chaturvedi, PhD, Michael B. Jordan, MD, Adam D. Cohen, MD, Vera Krymskaya, PhD, Arthur H Rubenstein, MBBCh, Frits van Rhee, MD PhD, Thomas S Uldrick, MDMS

Blood (2017) 130 (Supplement 1): 3593.

https://doi.org/10.1182/blood.V130.Suppl_1.3593.3593

Published: 2017

Journal Articles

Differential ICAM3 Gene Expression Correlates with Susceptibility to Natural Killer Cell-Mediated Lysis in Multiple Myeloma

Tarun K. Garg, PhD, Ricky D Edmondson, PhD, Shweta S. Chavan, PhD, Katie Stone, BS, Justin M Stivers, Jessica I Warden, Veronica Macleod, Charles M Skinner, Joshuah D Lingo, Amy D Greenway, Junaid Khan, Donald Johann, MD MS, Christoph Heuck, MD, Bart Barlogie, MD PhD, Gareth J Morgan, MDPhD, Joshua Epstein, DSc, Frits van Rhee, MD PhD

Blood (2015) 126 (23): 2990.

https://doi.org/10.1182/blood.V126.23.2990.2990

Published: 2015

Journal Articles

Multiple Myeloma Cells Modulate ICAM-3 To Evade Natural Killer Cell-Mediated Lysis

Tarun K. Garg, PhD, Ricky D Edmondson, PhD, Shweta S. Chavan, PhD, Junaid Khan, PhD, Susann Szmania, BS, Justin Stivers, BS, Veronica Macleod, BS, Katie Stone, BS, Emily Woods, BS, Donald Johann, MD, MS, Bart Barlogie, MD, PhD, Joshua Epstein, DSc, Frits van Rhee, MD, PhD

Blood (2013) 122 (21): 3105.

https://doi.org/10.1182/blood.V122.21.3105.3105

Published: 2013

Journal Articles

Impact Of Elotuzumab Therapy On Circulating and Ex Vivo Activated/Expanded Autologous Natural Killer (Auto-ENK) Cell Activity

Susann Szmania, BS, Amy D Greenway, BS, Joshuah D Lingo, BS, Katie Stone, BS, Junaid Khan, PhD, Tarun K. Garg, PhD, Nathan M Petty, MS, Susan B. Panozzo, BS, Emily Woods, BS, Jessica Warden, Joshua Epstein, DSc, Bart Barlogie, MD, PhD, Frits van Rhee, MD,PhD

Blood (2013) 122 (21): 5389.

https://doi.org/10.1182/blood.V122.21.5389.5389

Published: 2013

Journal Articles

Prognostic Significance of DNA/Cig Flow Cytometry Assay in the ‘'era” of Novel Therapies in Multiple Myeloma (MM).

Xenofon Papanikolaou, MD, Jackie Szymonifka, Susann Szmania, Katie Stone, Sarah Waheed, MD, Saad Z Usmani, MD FACP, Christoph Heuck, MD, Frits van Rhee, MD, PhD, Joshua Epstein, DSc, Antje Hoering, Bart Barlogie, MD

Blood (2012) 120 (21): 2918.

https://doi.org/10.1182/blood.V120.21.2918.2918

Published: 2012

Journal Articles

Expanded Natural Killer (NK) Cells for Immunotherapy: Fresh and Made to Order

Susann Szmania, Natalia Lapteva, PhD, Tarun K. Garg, PhD, Joshuah D Lingo, Amy D Greenway, Amberly Bost, Katie Stone, Junaid Khan, Emily Woods, Bijay Nair, MD, Dario Campana, MD, PhD, Joshua Epstein, DSc, Malcolm K. Brenner, MD, PhD, Adrian P. Gee, PhD, Michele H. Cottler-Fox, MD, Bart Barlogie, MD, PhD, Cliona M. Rooney, PhD, Frits van Rhee, MD, PhD

Blood (2012) 120 (21): 1912.

https://doi.org/10.1182/blood.V120.21.1912.1912

Published: 2012

Journal Articles

Fresh Ex Vivo Expanded Natural Killer Cells Demonstrate Robust Proliferation in Vivo in High-Risk Relapsed Multiple Myeloma (MM) Patients

Blood (2012) 120 (21): 579.

https://doi.org/10.1182/blood.V120.21.579.579

Published: 2012

Journal Articles

Myeloma Can Modulate Expanded Natural Killer Cell Function Through Multiple Mechanisms

Tarun K. Garg, PhD, Junaid Khan, Justin Stivers, Susann Szmania, Amy D Greenway, Joshuah D Lingo, Katie Stone, Emily Woods, Bart Barlogie, MD, PhD, Joshua Epstein, DSc, Frits van Rhee, MD, PhD

Blood (2012) 120 (21): 4020.

https://doi.org/10.1182/blood.V120.21.4020.4020

Published: 2012

Journal Articles

Autologous Expanded Natural Killer Cells As a New Therapeutic Option for High-Risk Myeloma

Tarun K. Garg, PhD, Junaid Khan, Susann Szmania, Amy D Greenway, Joshuah D Lingo, Amberly Moreno-Bost, Katie Stone, Antje Hoering, PhD, Emily Woods, Bijay Nair, MD, William Bellamy, PhD, Dario Campana, MD, PhD, Shmuel Yaccoby, PhD, Bart Barlogie, MD, Ph.D, Joshua Epstein, DSc, Frits van Rhee, MD, PhD

Blood (2011) 118 (21): 2918.

https://doi.org/10.1182/blood.V118.21.2918.2918

Published: 2011

Journal Articles

Adoptively Transferred Expanded Natural Killer Cells Inhibit Myeloma Tumor Growth In Vivo .

Tarun K. Garg, PhD, Susann Szmania, BS, Paul Malbrough, BS, Charles Ekworomadu, MS, Katie Stone, BS, Amberly Moreno-Bost, BS, Emily Woods, BS, Jumei Shi, MD, PhD, Shmuel Yaccoby, PhD, John D Shaughnessy, Jr., PhD, Bart Barlogie, MD, PhD, Dario Campana, MD, PhD, Frits van Rhee, MD, PhD

Blood (2009) 114 (22): 953.

https://doi.org/10.1182/blood.V114.22.953.953

Published: 2009

Journal Articles

Activation and Expansion of Natural Killer (NK) Cells with Potent Cytotoxicity for Multiple Myeloma

Jumei Shi, MD, PhD, Susann Szmania, BS, Guido Tricot, MD, PhD, Tarun K. Garg, PhD, Priyangi A Malaviarachchi, BS, Amberly Moreno-Bost, BS, Katie Stone, BS, Fenghuang Zhan, MD, PhD, Dario Campana, MD, PhD, John Shaughnessy, Jr., PhD, Bart Barlogie, MD, PhD, Frits van Rhee, MD, PhD

Blood (2008) 112 (11): 2758.

https://doi.org/10.1182/blood.V112.11.2758.2758

Published: 2008

NARROW

Storming the Castle with TCP

Characterization of the Immune Impact of Daratumumab By Mass Cytometry in Multiple Myeloma

Myeloma Patient-Derived Bone Marrow Serum Negatively Regulates Natural Killer Cell Activity

Personalized Therapy in Multicentric Castleman Disease Produces Excellent Outcomes in a Tertiary Referral Center

Treatment of Unresectable Unicentric Castleman Disease with Therapeutic Embolization

International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease

The IL15 Superagonist Complex ALT-803 Potently Enhances the Proliferative Capacity and Activity of in Vitro Expanded Natural Killer Cells

Virome Capture Sequencing in Castleman Disease Identifies Associations with Herpesviridae Family Members but No Novel Viruses

Quantification of Plasma Proteins from Idiopathic Multicentric Castleman Disease Flares and Remissions Reveals 'Chemokine Storm' and Separates Clinical Subtypes

Prolonged Remission Achieved in a Relapsing Idiopathic Multicentric Castleman Disease Patient with a Novel, Targeted Treatment Approach

Differential ICAM3 Gene Expression Correlates with Susceptibility to Natural Killer Cell-Mediated Lysis in Multiple Myeloma

Multiple Myeloma Cells Modulate ICAM-3 To Evade Natural Killer Cell-Mediated Lysis

Impact Of Elotuzumab Therapy On Circulating and Ex Vivo Activated/Expanded Autologous Natural Killer (Auto-ENK) Cell Activity

Prognostic Significance of DNA/Cig Flow Cytometry Assay in the ‘'era” of Novel Therapies in Multiple Myeloma (MM).

Expanded Natural Killer (NK) Cells for Immunotherapy: Fresh and Made to Order

Fresh Ex Vivo Expanded Natural Killer Cells Demonstrate Robust Proliferation in Vivo in High-Risk Relapsed Multiple Myeloma (MM) Patients

Myeloma Can Modulate Expanded Natural Killer Cell Function Through Multiple Mechanisms

Autologous Expanded Natural Killer Cells As a New Therapeutic Option for High-Risk Myeloma

Adoptively Transferred Expanded Natural Killer Cells Inhibit Myeloma Tumor Growth In Vivo .

Activation and Expansion of Natural Killer (NK) Cells with Potent Cytotoxicity for Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only